Health TrialsbyHealthPanel

Social Health, Activity Behaviors, and Quality of Life Among Young Adult Cancer Survivors

ConditionsAnatomic Stage I Breast Cancer AJCC v8Anatomic Stage IA Breast Cancer AJCC v8Anatomic Stage IB Breast Cancer AJCC v8Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage IIA Breast Cancer AJCC v8Anatomic Stage IIB Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IIIA Breast Cancer AJCC v8Anatomic Stage IIIB Breast Cancer AJCC v8Anatomic Stage IIIC Breast Cancer AJCC v8Central Nervous System NeoplasmClinical Stage I Cutaneous Melanoma AJCC v8Clinical Stage IA Cutaneous Melanoma AJCC v8Clinical Stage IB Cutaneous Melanoma AJCC v8Clinical Stage II Cutaneous Melanoma AJCC v8Clinical Stage IIA Cutaneous Melanoma AJCC v8Clinical Stage IIB Cutaneous Melanoma AJCC v8Clinical Stage IIC Cutaneous Melanoma AJCC v8Clinical Stage III Cutaneous Melanoma AJCC v8Hodgkin LymphomaMalignant Bone NeoplasmMalignant Brain NeoplasmMalignant Solid NeoplasmMalignant Testicular NeoplasmNon-Hodgkin LymphomaPathologic Stage I Cutaneous Melanoma AJCC v8Pathologic Stage IA Cutaneous Melanoma AJCC v8Pathologic Stage IB Cutaneous Melanoma AJCC v8Pathologic Stage II Cutaneous Melanoma AJCC v8Pathologic Stage IIA Cutaneous Melanoma AJCC v8Pathologic Stage IIB Cutaneous Melanoma AJCC v8Pathologic Stage IIC Cutaneous Melanoma AJCC v8Pathologic Stage III Cutaneous Melanoma AJCC v8Pathologic Stage IIIA Cutaneous Melanoma AJCC v8Pathologic Stage IIIB Cutaneous Melanoma AJCC v8Pathologic Stage IIIC Cutaneous Melanoma AJCC v8Pathologic Stage IIID Cutaneous Melanoma AJCC v8Prognostic Stage I Breast Cancer AJCC v8Prognostic Stage IA Breast Cancer AJCC v8Prognostic Stage IB Breast Cancer AJCC v8Prognostic Stage II Breast Cancer AJCC v8Prognostic Stage IIA Breast Cancer AJCC v8Prognostic Stage IIB Breast Cancer AJCC v8Prognostic Stage III Breast Cancer AJCC v8Prognostic Stage IIIA Breast Cancer AJCC v8Prognostic Stage IIIB Breast Cancer AJCC v8Prognostic Stage IIIC Breast Cancer AJCC v8Stage I Cervical Cancer AJCC v8Stage I Colorectal Cancer AJCC v8Stage I Differentiated Thyroid Gland Carcinoma AJCC v8Stage I Ovarian Cancer AJCC v8Stage I Thyroid Gland Medullary Carcinoma AJCC v8Stage I Uterine Corpus Cancer AJCC v8Stage IA Cervical Cancer AJCC v8Stage IA Ovarian Cancer AJCC v8Stage IA Uterine Corpus Cancer AJCC v8Stage IA1 Cervical Cancer AJCC v8Stage IA2 Cervical Cancer AJCC v8Stage IB Cervical Cancer AJCC v8Stage IB Ovarian Cancer AJCC v8Stage IB Uterine Corpus Cancer AJCC v8Stage IB1 Cervical Cancer AJCC v8Stage IB2 Cervical Cancer AJCC v8Stage IC Ovarian Cancer AJCC v8Stage II Cervical Cancer AJCC v8Stage II Colorectal Cancer AJCC v8Stage II Differentiated Thyroid Gland Carcinoma AJCC v8Stage II Ovarian Cancer AJCC v8Stage II Thyroid Gland Medullary Carcinoma AJCC v8Stage II Uterine Corpus Cancer AJCC v8Stage IIA Cervical Cancer AJCC v8Stage IIA Colorectal Cancer AJCC v8Stage IIA Ovarian Cancer AJCC v8Stage IIA1 Cervical Cancer AJCC v8Stage IIA2 Cervical Cancer AJCC v8Stage IIB Cervical Cancer AJCC v8Stage IIB Colorectal Cancer AJCC v8Stage IIB Ovarian Cancer AJCC v8Stage IIC Colorectal Cancer AJCC v8Stage III Cervical Cancer AJCC v8Stage III Colorectal Cancer AJCC v8Stage III Differentiated Thyroid Gland Carcinoma AJCC v8Stage III Ovarian Cancer AJCC v8Stage III Thyroid Gland Medullary Carcinoma AJCC v8Stage III Uterine Corpus Cancer AJCC v8Stage IIIA Cervical Cancer AJCC v8Stage IIIA Colorectal Cancer AJCC v8Stage IIIA Ovarian Cancer AJCC v8Stage IIIA Uterine Corpus Cancer AJCC v8Stage IIIA1 Ovarian Cancer AJCC v8Stage IIIA2 Ovarian Cancer AJCC v8Stage IIIB Cervical Cancer AJCC v8Stage IIIB Colorectal Cancer AJCC v8Stage IIIB Ovarian Cancer AJCC v8Stage IIIB Uterine Corpus Cancer AJCC v8Stage IIIC Colorectal Cancer AJCC v8Stage IIIC Ovarian Cancer AJCC v8Stage IIIC Uterine Corpus Cancer AJCC v8Stage IIIC1 Uterine Corpus Cancer AJCC v8Stage IIIC2 Uterine Corpus Cancer AJCC v8
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-39
SponsorUniversity of Southern California

About this trial

This study assesses how personal relationships (such as friendships, family relationships, or romantic partners) influence the physical activity (exercise) and well-being of young adult cancer survivors. Researchers also hope to learn how social relationships change after a cancer diagnosis, and how these changes might impact important health behaviors. The information provided may help researchers learn more about better ways to support young cancer patients in the future through interventions that help maintain good social relationships and health levels of physical activity.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Diagnosed and/or treated with cancer between ages 18-39 at USC hospitals.

Cancer types prototypical for adolescents and young adults (AYAs) and cancer stages I-III; select patients with stage IV disease may be eligible, with approval by the principal investigator (PI) and in consultation with the treating clinician.

Must be within three months of a de novo cancer diagnosis at recruitment and on/indicated for curative therapy (any modality). Patients may continue on adjuvant therapy throughout duration of the study.

Patients must have anticipated survival of >1-year at time of diagnosis.

Disqualifiers

Diagnosis of blood malignancies such as leukemias (these cancers have divergent treatment patterns of longer duration than other cancers and are more commonly pediatric cancers). Some early stage lymphomas with favorable prognoses may be eligible, with approval by the PI and in consultation with the treating clinician.

Primary language other than English or Spanish.

Inability to complete a survey and/or wear an accelerometer either per the patient or in consultation with the clinician's judgment.

Trial population

Patients diagnosed and/or treated with cancer between ages 18-39 at University of Southern California (USC) hospitals.

Trial design

Design model

Case-only

Time perspective

Prospective

Treatments tested in this trial

  • Medical Device Usage and Evaluation

    Other intervention

    Wear an actigraph GT3X-BT accelerometer

  • Quality-of-Life Assessment

    Other intervention

    Complete survey

  • Survey Administration

    Other intervention

    Complete survey

Treatment groups

250 Participants
are divided into 1 treatment group
Group A: Observational (actigraph, surveys)3 interventions

Trial outcomes

Primary outcomes

1

Rate of Change in trajectories of social health

Social health variables include the number, frequency and duration of hospitalizations, specifics of cancer diagnosis (i.e., stage at diagnosis, pertinent histology, recurrence or progression of disease), chemotherapy type, surgery related to cancer diagnosis, radiation field, immunotherapy type, and other relevant therapies related to cancer treatment. Changes in above variables will be measured using latent growth curve models to measure latent intercept (initial level), and the latent slope (rate of change) of social health variables during the course of therapy.

Time frame
Baseline up to 1 year
2

Rate of Change in trajectories of physical activity

Changes will be measured using latent growth curve models to measure latent intercept (initial level) and the latent slope (rate of change) of physical activity during the course of therapy.

Time frame
Baseline up to 1 year
3

Rate of Change in trajectories of quality of life

Changes will be measured using latent growth curve models to measure latent intercept (initial level) and the latent slope (rate of change) of quality of life during the course of therapy.

Time frame
Baseline up to 1 year
4

Moderation by gender

Will conduct multi-group analyses by the categories of study moderators (e.g., gender, race/ethnicity, socioeconomic status \[SES\], health status). The strengths of group-specific pathways to link social health and activity behaviors to quality of life will be compared using the chi-square (χ2) difference test of model fit. The log-likelihood values with (versus \[vs.\] without) the equality constraints on the group-specific pathways to determine if the strength of associations estimated in the models significantly differ by the groups of each moderator (e.g., gender: female vs. male).

Time frame
Up to 1 year

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

University of Southern California

Lead sponsor

National Cancer Institute (NCI)

Collaborator

Source ClinicalTrials.gov
Apply now